Skip to Main Content

Paper Details

Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results.
3
2023
BA, BA.4, COVID-19 mRNA, D614G, Omicron, SARS, SARS-CoV, SARS-CoV-2, Wuhan-Hu-1 mRNA, Wuhan-Hu-1 mRNA-1273, mRNA, mRNA-, mRNA-1273, mRNA-1273.222, participants
Author NameAffiliation
David C MontefioriDepartment of Surgery and Duke Human Vaccine Institute
  • 1 - 1

Datasets

Release 1.2